- Establishes Fiscal 2026 Guidance -
PIOMBINO DESE, Italy--(BUSINESS WIRE)--March 04, 2026--
Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the fourth quarter and full year 2025.
Fourth Quarter and Full Year 2025 Highlights (comparisons to prior-year periods)
-- For the fourth quarter of 2025, revenue increased 5% (7% on a constant
currency basis) to EUR346.5 million, and high-value solutions represented
49% of total revenue.
-- Gross profit margin increased 120 basis points to 30.9%, and adjusted
EBITDA margin increased 70 basis points to 28.2%, for the fourth quarter
of 2025.
-- Diluted earnings per share were EUR0.17, and adjusted diluted earnings
per share were EUR0.18 for the fourth quarter of 2025.
-- For the fiscal year 2025, revenue increased 7% (9% on a constant
currency basis) to EUR1.186 billion, and high-value solutions represented
46% of total revenue.
-- Gross profit margin increased 160 basis points to 29.0%, and adjusted
EBITDA margin increased 160 basis points to 25.1% for the fiscal year
2025.
-- For the fiscal year 2025, diluted earnings per share grew 19% to
EUR0.51, and adjusted diluted earnings per share increased 13% to
EUR0.54.
-- The Company is establishing its fiscal 2026 guidance. The Company
expects revenue in the range of EUR1.26 billion to EUR1.29 billion,
adjusted EBITDA in the range of EUR331.8 million to EUR346.9 million, and
adjusted diluted EPS in the range of EUR0.59 to EUR0.63.
Fourth Quarter 2025 Results
For the fourth quarter of 2025, total revenue increased 5% year-over-year (7% on a constant currency basis) to EUR346.5 million, driven by a 10% (13% on a constant currency basis) revenue increase from the Company's Biopharmaceutical and Diagnostic Solutions (BDS) Segment, which offset the anticipated revenue decline from the Engineering Segment. Revenue from high-value solutions increased 31%, year-over-year, to a record EUR171.4 million, representing 49% of total revenue for the fourth quarter of 2025.
In the fourth quarter of 2025, strong performance in the BDS Segment led to a 120 basis-point increase in gross profit margin to 30.9%, compared with the same period last year, and operating profit margin was 20.2%, consistent with the same period last year.
Net profit was EUR47.6 million, with diluted earnings per share of EUR0.17, for the fourth quarter of 2025, and adjusted net profit was EUR49.8 million with diluted earnings per share of EUR0.18. For the fourth quarter of 2025, adjusted EBITDA increased to EUR97.7 million, and the adjusted EBITDA margin improved 70 basis points to 28.2%, compared with the same period last year.
Franco Stevanato, Chief Executive Officer, commented, "We concluded fiscal year 2025 with another solid quarter that led to positive full--year performance underpinned by strong top-line growth, a favorable mix of high value solutions, and expanded margins. Biologics remain an important tailwind and in 2025 GLP1s represented approximately 19% to 20% of total Company revenue. There's no doubt that we have been successful in winning our fair share of the GLP1 market. This success is rooted in our long history of being a trusted partner to customers, our global footprint which provides supply chain security, and the quality of our products which have characteristics that resonate with our customers."
Biopharmaceutical and Diagnostic Solutions (BDS) Segment
Revenue grew 10% (13% on a constant currency basis) to EUR307.1 million for the fourth quarter of 2025, compared with the same period last year, driven by a 31% increase from high-value solutions to EUR171.4 million, which represented 56% of BDS Segment revenue. Revenue from other containment and delivery solutions decreased 9% to EUR135.7 million, compared with the same period last year, due to a decline in certain lower-value bulk products, as the Company transitions to a larger portfolio of high-value products aligned with its strategic investments.
For the fourth quarter of 2025, gross profit margin increased 50 basis points to 31.6%, and operating profit margin rose 50 basis points to 23.8%, compared with the same period last year, driven by: (i) a favorable mix of high value solutions, (ii) improvements as the Company scales commercial production in its new facilities, which remain dilutive to the corporate margin, and (iii) an improved vial market which led to higher vial production and better utilization. These positive trends were partially offset by the unfavorable impact from foreign currency translation and tariffs.
Engineering Segment
As expected, revenue from the Engineering Segment decreased 23% to EUR39.4 million for the fourth quarter of 2025, compared with the same period last year, driven by lower revenue from our glass converting and assembly lines businesses.
For the fourth quarter of 2025, gross profit margin for the Engineering Segment decreased 280 basis points to 15.8%, compared with the same period last year, and continued to be impacted by an unfavorable project mix and a lower volume of new work.
Balance Sheet and Cash Flow
As of December 31, 2025, the Company had cash and cash equivalents of EUR130.6 million, and net debt of EUR337.7 million.
For fiscal year 2025, capital expenditures totaled EUR294.9 million, as the Company continues to increase capacity in its new manufacturing facilities in Indiana and Italy. Cash flow from operating activities for fiscal year 2025 was EUR286.1 million. Cash used for the purchase of property, plant, and equipment, and intangible assets totaled EUR275.1 million. Increased operational cash flow and reduced capital expenditures resulted in EUR18.4 million of positive free cash flow for the year ended 2025.
The Company believes that it has adequate liquidity to fund its strategic priorities over the next twelve months through a combination of cash on hand, cash generated from operations, available credit lines, and the ability to access additional financing.
2026 Guidance
The Company is establishing its fiscal 2026 guidance and expects:
-- Revenue in the range of EUR1.26 billion to EUR1.29 billion;
-- Adjusted EBITDA in the range of EUR331.8 million to EUR346.9 million;
and
-- Adjusted diluted EPS in the range of EUR0.59 to EUR0.63.
Franco Stevanato, Chief Executive Officer, concluded, "We enter 2026 with positive momentum and a clear focus on disciplined execution. We operate in attractive, growing end markets with favorable secular tailwinds. Innovation across the industry continues to advance patient care and we remain mission critical to the delivery of innovative biologics. Biologics are expected to remain our fastest growing end market and a key driver to top-line growth and margin expansion as we continue to move up the value chain. In Latina and Fishers, we expect to increasingly benefit from improved utilization, efficiencies, and operating leverage, as we support our customers with quality and reliability."
Conference call: The Company will host a conference call and webcast at 8:30 a.m. $(ET)$ on Wednesday, March 4, to discuss financial results. During the call, management will refer to a slide presentation which will be available on the morning of the call on the "Financial Results" page under the Investor Relations section of the Company's website.
Pre-registration: Participants who pre-register will be given a conference passcode and unique PIN to gain immediate access to the call and bypass the live operator. We encourage participants to pre-register for the conference call using the following link: Pre-registration for STVN Q4 2025 earnings webcast.
Webcast: A live, listen-only webcast of the call will be available at the following link: STVN Q4 2025 webcast.
Dial in: Those who are unable to pre-register may dial in by calling:
Italy: +39 02 802 09 11 United Kingdom: +44 1 212 818004 United States: +1 718 705 8796 United States Toll Free: +1 855 265 6958
Questions during the call: Participants who wish to ask questions during the call should use the HD webphone link: STVN Q4 2025 Link for Questions
Replay: The webcast will be archived for three months on the Company's Investor Relations section of its website.
Forward-Looking Statements
This press release may include forward-looking statements. The words "establishing," "continued," "remain," "expected," "improved," "transitions," "scales," "believes," "expects," "continues," "growing," "expect," and other similar expressions (or their negative) identify certain of these forward-looking statements. These forward-looking statements are statements regarding the Company's intentions, beliefs or current expectations concerning, among other things, the Company's future financial performance, including revenue, operating expenses and ability to maintain profitability, and operational and commercial capabilities; the Company's expectations regarding the development of the industry and the competitive environment in which it operates; the expansion of the Company's plants and sites, and our expectations related to our capacity expansion; the global supply chain and the Company's committed orders; customer demand; the success of the Company's initiatives to optimize the industrial footprint, harmonize processes and enhance supply chain and logistics strategies; the Company's geographical and industrial footprint; and the Company's goals, strategies, and investment plans. The forward-looking statements in this press release are based on numerous assumptions regarding the Company's present and future business strategies and the environment in which the Company will operate in the
future. Forward-looking statements involve inherent known and unknown risks, uncertainties, and contingencies because they relate to events and depend on circumstances that may or may not occur in the future, and may cause the actual results, performance, or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements. Many of these risks and uncertainties relate to factors that are beyond the Company's ability to control or estimate precisely, such as conditions in the U.S. capital markets, negative global and domestic economic and political conditions, inflation, trade war and global tariff policies, the impact of the conflict between Russia and the Ukraine, the evolving events in Israel and Gaza, supply chain and logistical challenges and other factors such as the Company's ability to continue to obtain financing to meet its liquidity needs, changes in the geopolitical, social and regulatory framework in which the Company operates or in economic or technological trends or conditions. For a description of the risks that could cause the Company's future results to differ from those expressed in any such forward looking statements, refer to the risk factors discussed in our most recent annual report on Form 20-F, and our most recent filings with the U.S. Securities and Exchange Commission. Readers should therefore not place undue reliance on these statements, particularly not in connection with any contract or investment decision. Except as required by law, the Company assumes no obligation to update any such forward-looking statements.
Non-GAAP Financial Information
This press release contains non-GAAP financial measures. Please refer to the tables included in this press release for a reconciliation of non-GAAP financial measures.
Management monitors and evaluates our operating and financial performance using several non-GAAP financial measures, including Constant Currency Revenue, EBITDA, Adjusted EBITDA, Adjusted EBITDA Margin, Adjusted Operating Profit, Adjusted Operating Profit Margin, Adjusted Income Taxes, Adjusted Net Profit, Adjusted Diluted EPS, CAPEX, Free Cash Flow, Net Cash/(Debt), and Capital Employed. The Company believes that these non-GAAP financial measures provide useful and relevant information regarding its performance and improve its ability to assess our financial condition. While similar measures are widely used in the industry in which the Company operates, the financial measures it uses may not be comparable to other similarly titled measures used by other companies, nor are they intended to be substitutes for measures of financial performance or financial position as prepared in accordance with IFRS.
About Stevanato Group
Founded in 1949, Stevanato Group is a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries. The Group delivers an integrated, end-to-end portfolio of products, processes, and services that address customer needs across the entire drug life cycle at each of the development, clinical and commercial stages. Stevanato Group's core capabilities in scientific research and development, its commitment to technical innovation, and its engineering excellence are central to its ability to offer value added solutions to clients. To learn more, visit: www.stevanatogroup.com.
Consolidated Income Statement
(Amounts in EUR millions, except per share data)
For the three months For the years
ended December 31, ended December 31,
2025 % 2024 % 2025 % 2024 %
Revenue 346.5 100.0% 330.6 100.0% 1,186.3 100.0% 1,104.0 100.0%
Costs of Sales 239.6 69.1% 232.4 70.3% 842.4 71.0% 801.7 72.6%
----- ----- ----- ----- ------- ----- ------- -----
Gross Profit 106.9 30.9% 98.2 29.7% 343.9 29.0% 302.3 27.4%
Other Operating
Income 3.5 1.0% 5.5 1.7% 8.2 0.7% 9.1 0.8%
Selling and
Marketing
Expenses 7.9 2.3% 5.9 1.8% 28.2 2.4% 24.9 2.3%
Research and
Development
Expenses 5.8 1.7% 5.6 1.7% 25.4 2.1% 31.7 2.9%
General and
Administrative
Expenses 26.6 7.7% 25.4 7.7% 99.7 8.4% 93.7 8.5%
----- ----- ----- ----- ------- ----- ------- -----
Operating Profit 70.1 20.2% 66.8 20.2% 198.8 16.8% 161.1 14.6%
Finance Income 0.3 0.1% 5.6 1.7% 13.0 1.1% 13.5 1.2%
Finance Expense 4.6 1.3% 7.8 2.4% 22.7 1.9% 14.3 1.3%
----- ----- ----- ----- ------- ----- ------- -----
Profit Before Tax 65.8 19.0% 64.6 19.6% 189.1 15.9% 160.3 14.5%
Income Taxes 18.2 5.3% 16.3 4.9% 49.3 4.2% 42.5 3.9%
----- ----- ----- ----- ------- ----- ------- -----
Net Profit 47.6 13.7% 48.3 14.6% 139.8 11.8% 117.8 10.7%
Earnings per
share
Basic earnings
per common
share 0.17 0.18 0.51 0.43
Diluted earnings
per common
share 0.17 0.18 0.51 0.43
Average common
shares
outstanding 273.0 272.9 273.0 271.1
Average shares
assuming
dilution 273.0 272.9 273.0 271.2
Reported Segment Information
(Amounts in EUR millions)
For the three months ended December 31, 2025
Adjustments,
eliminations
Biopharmaceutical and
and Diagnostic unallocated
Solutions Engineering items Consolidated
------------------ ----------- ------------ ------------
External
Customers 307.1 39.4 -- 346.5
Inter-Segment 0.2 35.9 (36.1) --
----------------- ----------- ------------ ------------
Revenue 307.2 75.3 (36.1) 346.5
----------------- ----------- ------------ ------------
Gross Profit 97.0 11.9 (1.9) 106.9
----------------- ----------- ------------ ------------
Gross Profit
Margin 31.6% 15.8% 30.9%
----------------- ----------- ------------ ------------
Operating Profit 73.1 6.9 (9.9) 70.1
----------------- ----------- ------------ ------------
Operating Profit
Margin 23.8% 9.1% 20.2%
----------------- ----------- ------------ ------------
For the three months ended December 31, 2024
Adjustments,
eliminations
Biopharmaceutical and
and Diagnostic unallocated
Solutions Engineering items Consolidated
------------------ ----------- ------------ ------------
External
Customers 279.4 51.2 -- 330.6
Inter-Segment 1.1 56.1 (57.2) --
----------------- ----------- ------------ ------------
Revenue 280.5 107.3 (57.2) 330.6
----------------- ----------- ------------ ------------
Gross Profit 87.2 20.0 (9.0) 98.2
----------------- ----------- ------------ ------------
Gross Profit
Margin 31.1% 18.6% 29.7%
----------------- ----------- ------------ ------------
Operating Profit 65.5 16.4 (15.0) 66.9
----------------- ----------- ------------ ------------
Operating Profit
Margin 23.3% 15.3% 20.2%
----------------- ----------- ------------ ------------
For the year ended December 31, 2025
Adjustments,
eliminations
Biopharmaceutical and
and Diagnostic unallocated
Solutions Engineering items Consolidated
------------------ ----------- ------------ ------------
External
Customers 1,038.2 148.1 -- 1,186.3
Inter-Segment 2.2 132.9 (135.1) --
----------------- ----------- ------------ ------------
Revenue 1,040.3 281.0 (135.1) 1,186.3
----------------- ----------- ------------ ------------
Gross Profit 328.1 31.0 (15.3) 343.9
----------------- ----------- ------------ ------------
Gross Profit
Margin 31.5% 11.0% 29.0%
----------------- ----------- ------------ ------------
Operating Profit 220.4 9.3 (31.0) 198.8
----------------- ----------- ------------ ------------
Operating Profit
Margin 21.2% 3.3% 16.8%
----------------- ----------- ------------ ------------
For the year ended December 31, 2024
Adjustments,
eliminations
Biopharmaceutical and
and Diagnostic unallocated
Solutions Engineering items Consolidated
------------------ ----------- ------------ ------------
External
Customers 933.7 170.3 -- 1,104.0
Inter-Segment 4.0 187.3 (191.4) --
----------------- ----------- ------------ ------------
Revenue 937.8 357.6 (191.4) 1,104.0
----------------- ----------- ------------ ------------
Gross Profit 268.8 56.2 (22.6) 302.3
----------------- ----------- ------------ ------------
Gross Profit
Margin 28.7% 15.7% 27.4%
----------------- ----------- ------------ ------------
Operating Profit 165.6 33.1 (37.6) 161.1
----------------- ----------- ------------ ------------
Operating Profit
Margin 17.7% 9.3% 14.6%
----------------- ----------- ------------ ------------
Cash Flow
(Amounts in EUR millions)
For the three For the years
months ended ended December
December 31, 31,
2025 2024 2025 2024
------ -------- ------ --------
Cash flow from
operating
activities 94.1 43.6 286.1 155.8
Cash flow used
in investing
activities (94.4) (91.0) (272.9) (310.2)
Cash flow from
financing
activities 17.2 66.3 22.1 183.2
----- -------- ------ --------
Net change in
cash and cash
equivalents 16.9 18.9 35.2 28.8
----- -------- ------ --------
Non-GAAP Financial Information
This press release contains non-GAAP financial measures. Please refer to "Non-GAAP Financial Information" and the tables included in this press release for a reconciliation of non-GAAP financial measures.
Reconciliation of Revenue to Constant Currency Revenue
(Amounts in EUR millions)
Biopharmaceutical
Three months ended and Diagnostic
December 31, 2025 Solutions Engineering Consolidated
Reported Revenue
(IFRS GAAP) 307.1 39.4 346.5
Effect of changes
in currency
translation
rates 8.0 -- 8.0
----------------- ----------- ------------
Organic Revenue
(Non-IFRS GAAP) 315.1 39.4 354.5
----------------- ----------- ------------
Biopharmaceutical
Year ended December and Diagnostic
31, 2025 Solutions Engineering Consolidated
Reported Revenue
(IFRS GAAP) 1,038.2 148.1 1,186.3
Effect of changes
in currency
translation
rates 17.7 -- 17.7
----------------- ----------- ------------
Organic Revenue
(Non-IFRS GAAP) 1,055.9 148.1 1,204.0
----------------- ----------- ------------
Reconciliation of EBITDA
(Amounts in EUR millions)
For the three For the years
months ended ended December
December 31, Change 31, Change
2025 2024 % 2025 2024 %
---------------- ----- -------- ------ ----- -------- ------
Net Profit 47.6 48.3 (1.6)% 139.8 117.8 18.7%
Income Taxes 18.2 16.3 11.4% 49.3 42.5 15.9%
Finance Income 0.3 5.6 (94.3)% 13.0 13.5 (3.9)%
Finance
Expenses 4.6 7.8 (40.8)% 22.7 14.3 58.0%
---- -------- ------ ----- -------- ------
Operating
Profit 70.1 66.8 4.8% 198.8 161.1 23.4%
Depreciation
and
amortization
and impairment
of PPE 24.6 19.8 24.8% 88.6 80.7 9.8%
---- -------- ------ ----- -------- ------
EBITDA 94.7 86.6 9.4% 287.4 241.8 18.8%
---- -------- ------ ----- -------- ------
Calculation of Net Profit Margin, Operating Profit Margin, Adjusted EBITDA
Margin and Adjusted Operating Profit Margin
(Amounts in EUR millions)
For the three months For the year
ended December 31, ended December 31,
2025 2024 2025 2024
------ -------- ------- --------
Revenue 346.5 330.6 1,186.3 1,104.0
Net Profit Margin (Net
Profit/ Revenue) 13.7% 14.6% 11.8% 10.7%
Operating Profit Margin
(Operating Profit/
Revenue) 20.2% 20.2% 16.8% 14.6%
Adjusted EBITDA Margin
(Adjusted EBITDA/
Revenue) 28.2% 27.5% 25.1% 23.5%
Adjusted Operating
Profit Margin (Adjusted
Operating Profit/
Revenue) 21.1% 21.5% 17.7% 16.2%
Reconciliation of Reported and Adjusted EBITDA, Operating Profit, Income
Taxes,
Net Profit, and Diluted EPS
(Amounts in EUR millions, except per share data)
Three months Income
ended December Operating Taxes Net Diluted
31, 2025 EBITDA Profit (4) Profit EPS
----------------- ------- --------- ------ ------ -------
Reported 94.7 70.1 18.2 47.6 0.17
Adjusting
items:
Start-up costs
new plants (1) 2.0 2.0 0.5 1.4 0.01
Restructuring
and related
charges (2) 1.0 1.0 0.3 0.8 0.00
------ --------- ------ ------ -------
Adjusted 97.7 73.1 19.0 49.8 0.18
------ --------- ------ ------ -------
Adjusted Margin 28.2% 21.1% -- -- --
Three months Income
ended December Operating Taxes Net Diluted
31, 2024 EBITDA Profit (4) Profit EPS
----------------- ------- --------- ------ ------ -------
Reported 86.6 66.8 16.3 48.3 0.18
Adjusting
items:
Start-up costs
new plants (1) 3.8 3.8 1.0 2.8 0.01
Restructuring
and related
charges (2) 0.4 0.4 0.1 0.3 0.00
Other severance
costs (3) 0.2 0.2 0.0 0.1 0.00
------ --------- ------ ------ -------
Adjusted 90.9 71.2 17.5 51.5 0.19
------ --------- ------ ------ -------
Adjusted Margin 27.5% 21.5% -- -- --
Year ended Income
December 31, Operating Taxes Net Diluted
2025 EBITDA Profit (4) Profit EPS
----------------- ------- --------- ------ ------ -------
Reported 287.4 198.8 49.3 139.8 0.51
Adjusting
items:
Start-up costs
new plants (1) 6.5 6.5 1.8 4.7 0.02
Restructuring
and related
charges (2) 4.1 4.1 1.0 3.1 0.01
------ --------- ------ ------ -------
Adjusted 298.0 209.4 52.1 147.6 0.54
------ --------- ------ ------ -------
Adjusted Margin 25.1% 17.7% -- -- --
Year ended Income
December 31, Operating Taxes Net Diluted
2024 EBITDA Profit (4) Profit EPS
----------------- ------- --------- ------ ------ -------
Reported 241.8 161.1 42.5 117.8 0.43
Adjusting
items:
Start-up costs
new plants (1) 13.0 13.0 3.5 9.5 0.04
Restructuring
and related
charges (2) 4.0 4.0 1.0 3.0 0.01
Other severance
costs (3) 0.4 0.4 0.1 0.3 0.00
------ --------- ------ ------ -------
Adjusted 259.2 178.5 47.1 130.6 0.48
------ --------- ------ ------ -------
Adjusted Margin 23.5% 16.2% -- -- --
(1) During the three months and the year ended December 31, 2025, the Group
recorded EUR2.0 million and EUR6.5 million, respectively, of start-up costs
for the new plants in Fishers, Indiana, United States, and in Latina, Italy.
During the three months and the year ended December 31, 2024, the Group
recorded EUR3.8 million and EUR13.0 million, respectively, of start-up costs
for the new plants in Fishers, Indiana, United States, and in Latina, Italy.
These costs primarily reflect labor expenses for training and travel of
personnel who are in the learning and development phase and not yet active in
the manufacturing of products, as well as the related recruitment costs.
(2) During the three months and the year ended December 31, 2025, the Group
recorded EUR1.0 million and EUR4.1 million, respectively, of restructuring and
related charges. During the three months and the year ended December 31, 2024,
the Group recorded EUR0.4 million and EUR4.0 million, respectively, of
restructuring and related charges. These amounts mainly reflect
employee-related costs associated with the reorganization of certain business
functions.
(3) During the three months and the year ended December 31, 2024, the Group
recorded EUR0.2 million and EUR0.4 million, respectively, related to personnel
expenses, including other severance costs.
(4) The income tax adjustment is calculated by multiplying the applicable
nominal tax rate to the adjusting items.
Capital Employed
(Amounts in EUR millions)
As of December 31, As of December 31,
2025 2024
---------------------- ------------------- ------------------
- Goodwill and
Other intangible
assets 86.8 83.6
- Right of Use
assets 12.4 15.7
- Property, plant,
and equipment 1,391.5 1,248.4
- Financial assets
- investments
FVTPL 0.2 0.2
- Other
non-current
financial assets 5.5 5.4
- Deferred tax
assets 103.9 95.3
------------------------ ------------------ ------------------
Non-current assets
excluding FV of
derivative financial
instruments 1,600.3 1,448.7
------------------------ ------------------ ------------------
- Inventories 268.2 245.2
- Contract Assets 180.5 168.5
- Trade
receivables 302.7 296.0
- Trade payables (263.3) (231.0)
- Advances from
customers (33.4) (16.6)
- Non-current
advances from
customers (98.8) (44.0)
- Contract
Liabilities (10.4) (16.5)
------------------------ ------------------ ------------------
Trade working capital 345.4 401.6
------------------------ ------------------ ------------------
- Tax receivables
and other
receivables 50.6 70.6
- Current
financial
receivables -
rent to buy
agreement 8.6 --
- Non-current
assets held for
sale -- 0.2
- Tax payables and
other
liabilities (100.8) (92.2)
- Current
Provisions (4.4) (4.1)
------------------------ ------------------ ------------------
Net working capital 299.3 376.1
------------------------ ------------------ ------------------
- Deferred tax
liabilities (13.3) (12.6)
- Employees
benefits (6.8) (7.2)
- Non-Current
Provisions (3.2) (2.8)
- Other
non-current
liabilities (52.1) (62.7)
------------------------ ------------------ ------------------
Total non-current
liabilities and
provisions (75.4) (85.3)
------------------------ ------------------ ------------------
Capital employed 1,824.2 1,739.4
------------------------ ------------------ ------------------
Net (debt)/ net cash (337.7) (335.0)
------------------------ ------------------ ------------------
Equity (1,486.5) (1,404.4)
------------------------ ------------------ ------------------
Total equity and net
debt (1,824.2) (1,739.4)
------------------------ ------------------ ------------------
Free Cash Flow
(Amounts in EUR millions)
For the three For the years
months ended ended December
December 31, 31,
2025 2024 2025 2024
------ -------- ------ --------
Cash Flow
from
Operating
Activities 94.1 43.6 286.1 155.8
Interest paid 2.0 3.6 7.0 7.4
Interest
received (0.2) (0.4) (1.4) (1.3)
Purchase of
property,
plant, and
equipment (89.3) (88.9) (263.8) (302.6)
Proceeds from
sale of
property,
plant, and
equipment 0.2 -- 1.9 3.2
Purchase of
intangible
assets (5.2) (2.3) (11.3) (11.0)
----- -------- ------ --------
Free Cash
Flow 1.5 (44.3) 18.4 (148.5)
----- -------- ------ --------
Net (Debt) / Net Cash
(Amounts in EUR millions)
As of December 31, As of December 31,
2025 2024
------------------- ------------------
Non-current financial
liabilities (347.4) (317.7)
Current financial
liabilities (123.5) (116.9)
Other non-current
financial assets -
Fair value of
derivatives
financial
instruments 0.3 --
Other current
financial assets 2.2 1.3
Cash and cash
equivalents 130.6 98.3
------------------ ------------------
Net (Debt)/ Net Cash (337.7) (335.0)
------------------ ------------------
CAPEX
(Amounts in EUR millions)
For the three For the year
months ended ended December
December 31, Change 31, Change
2025 2024 EUR 2025 2024 EUR
------ -------- ------ ----- -------- ------
Addition to
Property,
plants, and
equipment 95.9 77.7 18.2 283.6 275.6 8.0
Addition to
Intangible
Assets 5.3 2.3 3.0 11.3 11.0 0.3
----- -------- ------ ----- -------- ------
CAPEX 101.2 80.0 21.2 294.9 286.6 8.3
----- -------- ------ ----- -------- ------
Reconciliation of 2026 Guidance*
Reported and Adjusted EBITDA, Operating Profit, Net Profit, Diluted
EPS
(Amounts in EUR millions, except per share data)
Operating Net
Revenue EBITDA Profit Profit Diluted EPS
---------- --------- -------- --------- --------- -----------
1,260.0 - 317.7 - 212.7 - 149.6 -
Reported 1,290.0 332.9 227.8 160.7 0.55 - 0.59
Adjusting
items:
Start-up costs new
plants 14.1 14.1 10.3 0.04
-------- --------- --------- -----------
Adjusted 1,260.0 - 331.8 - 226.8 - 159.9 - 0.59 - 0.63
1,290.0 346.9 241.9 171.0
---------- -------- --------- --------- -----------
*Amounts may not add due to rounding
View source version on businesswire.com: https://www.businesswire.com/news/home/20260304625622/en/
CONTACT: Media
Caterina Tripepi
caterina.tripepi@stevanatogroup.com
U.S. Media
Taylor Gerrells
taylor.gerrells@teamlewis.com
Investor Relations
Lisa Miles
lisa.miles@stevanatogroup.com
Giacomo Guiducci
giacomo.guiducci@stevanatogroup.com
(END) Dow Jones Newswires
March 04, 2026 06:30 ET (11:30 GMT)